NanoViricides says NV-387 could help reduce metastatic cancer resurgence

NanoViricides (NNVC) reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of “sleeping” cancer cells due to viral infections. NV-387 has completed a Phase I clinical trial and is being advanced into Phase II clinical trials. Recently, increase in inflammation, and particularly the cytokine IL-6, caused by viral infections has been found to be linked to an increased risk of resurgence of metastatic cancer, in a study of COVID-19 and breast cancer, as well as Influenza virus infections and cancer . This study has further substantiated that viral infections can lead to resurgence of metastatic cancers by re-activating “sleeping” cancer cells. Thus NV-387 treatment could have a strong impact in the treatment of cancer patients in remission who suffer from a viral infection that could lead to the cancer returning with metastasis to multiple sites in the body.